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REPORTS 
Epidermal Growth Factor Stimulates Release of Arachidonic Acid in Pig 
Epidermis 
TAKASHI AOYAGI, M.D., HIDEKO SUYA, B.Sc., NAOKO KATO, M.D., 0SAMU NEMOTO, M.D., 
HITOSHI KOBAYASHI, M.D., AND YUSHO MIURA, M.D. 
Department of Dermatology, Hokkaido University School of Medicine, Sapporo, Japan 
Epidermal growth factor (EGF) at physiologic concen-
trations (0.00 1-0.1~-tg/ml) stimulated the release of [14C] 
arachidonic acid [14C-AA] from pig epidermis. Although 
EGF stimulated the release of AA in the absence of 
exogenously added calcium to some extent, the addition 
of calcium (0.3-1.2 mM) significantly potentiated the 
release of AA stimulated by EGF. Ionophore A23187, 
which is known to stimulate phospholipase A2 activity 
by opening the calcium gates, potentiated the EGF-stim-
ulated release of AA. The stimulatory effect of EGF was 
partially inhibited by the addition of mepacrine (70% 
inhibition at 10 ~-tM) and by the pretreatment of hydro-
cortisone (60% inhibition at 1.0 ~-tM). The loss of 14C-
labeled phospholipids in pig epidermis was mainly due 
to the degradation of 14C-labeled phosphatidylcholine. 
Present results and recent reports by other workers 
suggest that EGF stimulates phospholipase A2 activity 
and result in the increased release of AA. 
Epidermal growth factor (EGF) has various important bio-
logic roles on cellular activities [1 - 3]. Concerning the action 
mechanism, EGF binds the EGF-specific receptor and subse-
quently activates the tyrosine-specific protein kinase [ 4,5]. As 
EGF is inhibitory to the proliferation of A431 cells which have 
an exclusively increased number of the EGF receptors [6], it 
may be considered that if the EGF action is mediated through 
tyrosine phosphorylation, the effect of EGF on cell growth may 
depend on other processes. EGF shares a number of biologic 
activities with phorbol ester which is known as an activator of 
phospholipase A2 [7] . Furthermore, it is reported that EGF 
stimulates phosphatidylinositol (PI) turnover [8,9], calcium 
influx [8], a nd protein kinase C [10] of A431 cells. This evidence 
prompted us to study the possibility of phospholipase A2 acti-
vation by EGF. The present study reports that EGF signifi-
cantly stimulated the release of arachidonic acid (AA) from 
membrane phospholipids of pig epidermis. The action mecha-
nism of EGF on the AA metabolism will be discussed. 
MATERIALS AND METHODS 
Skin slices were taken from the backs of domestic pigs, weighing 6-
8 kg, by a Castroviejo keratome set at a 0.2-mm depth . As skin slices 
thus obtained contain mainly epidermis (80-90%) (11] , these are called 
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Abbreviations: 
AA: arachidonic acid 
BSA: bovine serum albumin 
EGF: epidermal growth factor 
PC: phosphatidylcholine 
PE: phosphatidylethanolamine 
PG: prostaglandin 
PI: phosphatidylinositol 
PS: phosphatidylserine 
"epidermal slices." During this procedure, pigs were anesthetized i.p. 
with Nembutal (20- 30 mg/kg). Epidermal slices were kept in RPMI 
1640 medium at 4•c; they were then cut into 5 x 10 mm squares and 
used within 30 min. To obtain pure epidermal sheets, skin slices (0.3 
mm thick) were treated with Dispase (1000 units/ml) at 4 ·c for 20 h. 
Epidermal slices or pure epidermal sheets were floated in RPMI 1640 
medium with bovine serum albumin (essentially fatty acid-free) (BSA) 
[12] in the presence of 0.1 !lCi/ml [1-"C]arachidonic acid (["C]AA). 
The incubation for prelabeling was carried out at 37•c for 4 h in a 
high-humidity incubator in a mixture of 5% C02 in air. After prelabel-
ing with ["C]AA, epidermal slices or pure epidermal sheets were 
removed and washed twice in calcium-free RPMI 1640 with 1 mM 
EGTA. This prelabeling resulted in 62% incorporation of added ["C] 
AA into phospholipids. Epidermal slices or pure epidermal sheets were 
then treated with various test drugs in calcium-free RPMI with or 
without calcium supplemented with 2% BSA at 37•c for indicated 
periods [12]. The incubation was terminated by removing the samples 
from the medium immediately. The radioactivity of the released (14C] 
AA in the medium (2 ml) was determined by a scintillation counter. 
The released ["C]AA radioactivity was more than 85% of the total 
radioactivity recovered from the medium (experimental details will be 
described late r). Protein contents of the samples were measured by the 
method of Lowry eta! with BSA as a standard [13] . 
Pure epidermal sheets were used for the extraction and separation 
of phospholipids. The samples prelabeled with [' 4C)AA (0.1 llCi/mll 
for 4 h were treated with EGF (0.1 llg/ml) for 20 min at 37·c. The 
samples were removed at 0 and 20 min, and immediately frozen between 
2 dry-ice plates. The samples were then homogenized with a glass 
homogenizer in 3 ml of CHC13: CH30H (2:1) at 4 ·c, followed by adding 
1 ml of 2 M KCI solution. The homogenates were vigorously shaken 
and separated into 2 phases by centrifugation at lOOO g for 10 min. 
After the lower phase was washed with 2 M KCl, a part of it was used 
for the phospholipid analysis. Standard phospholipids were added as 
carriers to the sample solution, and the solvent was evaporated to 
dryness. The residue was dissolved in an appropriate volume of chlo-
roform (86% of the total radioactivity was extracted). 
The extract was spotted on thin- layer plates (precoated Silica Gel G 
Plate, Wako Chern., Japan). The plate was developed with chloro-
form:methanol:28% aqueous ammonia (60:35:8) for the separation of 
each phospholipid. Phospholipids on the plates were visualized by 
exposing to iodine vapor. The spots were scraped off and the radioac-
tivity in each spot was determined. The tota l radioactivity of separated 
phospholipids reached 98% of the sample applied. 
For the extraction of AA from the incubation medium, the medium 
was lyophilized and the residue was dissolved in chloroform:methanol 
(2:1). The plates on which the samples were spotted were developed by 
benzene:dioxane:acetic acid (20:20:1) for the separation of AA. The 
radioactivity of AA spot was determined by a scintillation counter. 
The following chemicals were obtained from the indicated sources: 
["C]AA (sp act 58 mCi/mmol) (Amersham, Tokyo); EGF (Collabora-
tive Research Inc., Waltham, Massachusetts); Dispase (Godo Shusei, 
Tokyo); BSA (essentially fatty acid-free), mepacrine, hydrocortisone 
(Sigma Chemical Co., St. Louis, Missouri); phosphatidylcholine (PC) , 
phosphatidylinositol (PI), phosphatidylethanolamine (PE), and phos-
phatidylserine (PS) (PL Biochemicals, Milwaukee, Wisconsin); Iono-
phore A23187 (Calbiochem-Behringer Co., San Diego, California); 
RPMI 1640 and calcium-free RPMI 1640 (Microbiological Associates, 
Walkersville, Maryland). All other chemicals and drugs were of ana-
lyt ical reagent grade. 
RESULTS 
Epidermal slices prelabeled with [14C]AA were treated with 
EGF at various concentrations in the presence or absence of 
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TABLE I. Effect of epidermal growth factor (EGF) on the release of AA 
[ "C ]AA released 
Control 
EGF: 
0.001 llg/ ml 
0.01 llg/ ml 
0.1 llg/ml 
1.0 11g/ml 
(dpm/mg protein x 102 ) 
703 ± 9 (4) 
1124 ±51 (4)" 
1366 ± 136 (4)" 
1934 ± 184 (4)" 
1938 ± 212 (4)" 
Epidermal slices prelabeled with ["C]AA (0.1 llCifml) were treated 
with EGF at various concentrations at 37"C for 20 min. The amount 
of ["C]AA released in the medium was determined and expressed as 
dpm/mg protein X 102 ± SEM. Number of samples shown in parenthe-
ses. 
• Statistically significant. 
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FIG 1. Effect of EG F on t he release of AA. Epidermal slices (A) or 
pure epidermal sheets (B) prelabeled with ["C]AA (0.1 llCi/ml) were 
treated with (.___.) or without (0-0) EGF (0.1 llg/ml) at 37"C 
for 30 min. At indicated periods, the samples were removed from the 
medium and the amount of ["C]AA released in the medium was 
determined. Each point represents the mean of triplicate determina-
tions. 
calcium for 20 min. EGF significantly stimulated the release of 
AA as shown in Table I. Epidermal slices or pure epidermal 
sheets prelabeled with [14 C]AA were also treated with EGF at 
0.1 ,ug/ml in the presence of calcium (1.2 mM) for various 
incubation periods. EGF significantly stimulated the release of 
AA as early as at 5 min, and this stimulatory effect of EGF 
reached its maximum at 20 min in epidermal slices (Fig 1A ). 
The release of AA from pure epidermal sheets stimulated by 
EGF also became evident at 5 min and reached its maximum 
at 20 min (Fig lB). The amount of AA released in the medium 
was more than 85% of the total radioactivity recovered from 
the medium (data not shown). 
As shown in Fig 2A, EGF significantly stimulated the release 
of AA in the presence of exogenously added calcium, although 
EGF also stimulated the release of AA in the absence of 
exogenously added calcium to some extent. The stimulatory 
effect of EGF was observed at physiologic concentrations 
(0.001- 0.1 !Lg/ml) and significantly potentiated by exogenously 
added calcium. In order to evaluate the calcium dependency of 
the EGF stimulation, calcium at various concentrations was 
added to the containing 0.1 ,ug/ml EGF medium, at which the 
maximum stimulatory effect of EGF was obtained. As shown 
in Fig 2B, the presence of 0.3-1.2 mM calcium significantly 
potentiated the release of AA stimulated by EGF. 
The release of AA stimulated by EGF was partially inhibited 
by the addition of mepacrine, an inhibitor of phospholipase A2 
(about 70% inhibition at 10 !LM) (Fig 3A ). Pretreatment with 
hydrocortisone, known to synthetize an inhibitor protein of 
phospholipase A2, also resulted in 60% inhibition of the AA 
release stimulated by EGF (Fig 3B). 
The presence of anti-EGF serum completely eliminated the 
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FIG 2. Effect of calcium on the EGF-stimulated AA release. A, 
Epidermal slices prelabeled with ["C]AA (0.1 llCi/ml) were treated 
with or without EGF at various concentrations in the presence 
(.___.) or absence (0-0) of 1.2 mM calcium. The amount of [14C] 
AA released in the medium was determined and expressed as % of the 
maximum AA release observed at 0.1 llg/ml of EGF in the presence of 
calcium. Each point represents the mean of duplicate determinations. 
B, Epidermal slices prelabeled with [14C]AA (0.1 llCi/ ml) were treated 
with (.....__.) or without (0-0) EGF at 0.1 llg/ml in the presence 
or absence of calcium at various concentrations (0.3-1.2 mM). The 
amount of ["C]AA released in the medium was determined and ex-
pressed as % of the maximum AA release observed at 1.2 mM of 
calcium. Each point represents the mean of duplicate determinations. 
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FIG 3. Inhibitory effects of mepacrine and hydrocortisone on the 
EGF-stimulated AA release. A, Epidermal slices prelabeled with [14C] 
AA (0.1 llCi/ ml) were treated with EGF (0.1 llg/ ml) in the presence or 
absence of mepacrine at various concentrations. The amount of [14C] 
AA released in the medium was determined and expressed as % of the 
maximum AA release observed at 0.1 llg/ ml of EGF (100%). Each point 
represents the mean of duplicate determinations. B, For the hydrocor-
t isone study, epidermal slices pretreated with or without hydrocortisone 
at various concentrations at 37"C for 22 h were prelabeled with ["C] 
AA (O.l11Ci/ml) . Epidermal slices were then treated with EGF (0.1 llg/ 
ml) . The amount of [14C]AA released in the medium was determined 
and expressed as % of the maximum AA release observed at 0.1 llg/ ml 
of EGF. Each point represents the mean (%) in duplicates. 
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FIG 4. Additive effect of EGF and A23187 on the AA release. A, 
Epidermal slices prelabeled with ["C]AA (0.1 !LCi/ml) were treated 
with A23187 (5 JLM) in the presence (.__.) or absence (0---0) of 
EGF at various concentrations. The amount of ["C]AA released in the 
medium was determined and expressed as % of the maximum AA 
release observed at 5 !LM of A23187 in the presence of EGF at 0.1 !Lg/ 
mi. Each point represents the mean of duplicate determinations. B, 
Epidermal slices prelabeled with ["C]AA (0.1 !LCi/ml) were treated 
with EGF (0.1 !Lg/ml) in the presence (.__.) or absence (0---0) 
of A23187 at various concentrations. The amount of ["C]AA released 
in the medium was determined and expressed as % of the maximum 
AA release observed at 0.1 !Lg/ml of EGF in the presence of A23187 at 
16 !LM . Each point represents the mean of duplicate determinations. 
TABLE II. Degradation of "C-lobeled phospholipids by EGF 
PC PE PI+ PS 
EGF (0.1JLg/ml) 68.5 ± 6.2 (6)" 92.6 ± 2.2 (6) 93.3 ± 4.1 (6) 
Pure epidermal sheets were prelabeled with ["C]AA (0.1 !LCi/ml) at 
37"C for 4 h. After washing, the incubation was initiated by the addition 
of EGF (0.1 !Lg/ml) at 37"C for 20 min and terminated by freezing 
samples between 2 dry-ice plates. Each value is expressed as % ± SEM 
of 0 time (at the end of prelabeling). Number of samples shown in 
parentheses. EGF = epidermal growth factor, PC = phosphatidylcho-
line, PE = phosphatidylethanolamine, PI = phosphatidylinositol, PS 
= phosphatidylserine. 
" Statistically significant (p < 0.01) . 
st imulatory effect of EGF on the release of AA when EGF and 
anti-EGF serum were preincubated for 20 min at 37"C before 
treatment (data not shown). 
Ionophore A23187 (A23187) is known to stimulate phospho-
lipase A2 activity by opening the calcium gates. As shown in 
Fig 4A, A23187 at 5 11M stimulated the release of AA. When 
EGF at various concentrations was added, the stimulatory 
effect of A23187 was potentiated by increasing the EGF con-
centrations. EGF at 0.1 11g/ml stimulated the release of AA as 
shown in Fig 4B. When A23187 at various concentrations was 
added, the stimulatory effect of EGF was also potentiated. 
T o detect the source of [14C)AA released in the medium, 
phospholipids were extracted from pure epidermal sheets and 
analyzed by thin-layer chromatography. As shown in Table II, 
14C-labeled PC 'was significantly degraded, while other phos-
pholipids such as PI, PE, and PS were not significantly de-
graded. 
DISCUSSION 
It is becoming increasingly apparent that phospholipase ac -
tivit ies may be important in regulating a variety of biologic 
processes such as secretion, chemotaxis, calcium mobilization, 
prostaglandin synthesis, and hydroxyeicosatetraenoic acid syn-
thesis. Since enhanced phospholipase A2 activity leading to an 
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increased AA content is present in both involved and unin-
volved psoriatic skin [14], and levels of 12-HETE, prostaglan-
din E 2, (PGE2) and PGF2" are increased in involved psoriatic 
epidermis [15], it may be considered that the AA metabolism 
plays a key role in the pathogenesis and treatment of psoriasis. 
It is generally accepted that the rate-limiting step in AA 
metabolism is the release of AA from membrane phospholipids. 
Factors that stimulate the release of AA may therefore activate 
the whole cascade of AA metabolism [16] . These stimuli can 
be physical, as in trauma and UVB irradiation, or biochemical, 
as in immunologic specific processes and immunologic nonspe-
cific processes. There are various chemicals that stimulate the 
release of AA in various types of cells, such as A23187, phorbol 
ester (TPA), melittin, thrombin, etc. 
EGF is a low-molecular-weight peptide that stimulates DNA 
synthesis and cell proliferation in a variety of cell types [1- 3]. 
It is also reported that EGF stimulates PI turnover [8,9], 
calcium influx [8], and protein kinase C [10] of A431 cells. 
The present study revealed that EGF at physiologic concen-
trations (0.001-0.1 !Lg/ml) significantly stimulated the release 
of AA from membrane phospholipids of epidermal slices and 
pure epidermal sheets of pig skin. This stimulation was com-
pletely eliminated by the addition of anti-EGF serum and 
partially inhibited by mepacrine, an inhibitor of phospholipase 
A2. Hydrocortisone, known to synthesize an inhibitor protein 
of phospholipase A2 [17], also inhibited the EGF-stimulated 
release of AA. 
These results strongly suggest that EGF specifically stimu-
lates the release of AA from membrane phospholipids of pig 
epidermis through the activation of phospholipase A2. 
The precise action site of EGF to stimulate the release of AA 
through activation of phospholipase A2 is not fully understood. 
Interestingly enough, EGF and A23187 potentiated the release 
of AA independently of each other. A23187 is thought to open 
the calcium gates, to initiate calcium influx, and to lead to the 
activation of phospholipase A2. The effect of A23187 was 
entirely calcium-dependent in this system (data not shown), 
while EGF slightly stimulated the release of AA in the absence 
of exogenously added calcium, and the EGF-stimulated AA 
release was significantly potentiated by the addition of calcium 
(0.3- 1.2 mM) . It has recently been reported thatEGF stimulates 
PI turnover [8,9], calcium influx [8], and protein kinase C [10] 
of A431 cells. Although the effect of EGF on PI turnover of the 
intact cell system of pig epidermis is under investigation, these 
data and our results suggest that EGF stimulates PI turnover, 
initiates calcium mobilization (both extra- and intracellular), 
leads to the activation of phospholipase A2, and results in the 
increased release of AA. 
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